Data from the phase 3b STEP UP trial demonstrate that the 7.2 mg semaglutide dose provides superior weight reduction compared ...

Doctors explain the differences between the Wegovy pill and injection in terms of efficacy, side effects, and more. They ...

On December 22, 2025, the U.S. Food and Drug Administration (FDA) approved an oral pill form of Wegovy — a glucagon-like peptide-1 (GLP-1) receptor agonist medication for weight loss. Until now, ...

Wegovy is a prescription medicine used for weight loss, to reduce cardiovascular risks, and to treat metabolic dysfunction-associated steatohepatitis (MASH). It is available in two forms: a liquid for ...

GLP-1 (glucagon-like peptide-1 receptor agonists) like Ozempic and Wegovy continue to make headlines as more research points to the benefits of taking these medications. Traditionally, patients ...

Novo Nordisk’s 7.2 mg dose of Wegovy will compete against Lilly’s GLP-1 injection.

Chief Medical Officer at Central DuPage Hospital Dr. Tom Moran joins Bob Sirott to discuss a study that looks at the correlation between caffeine intake and the risk for diabetes, the new federal ...

The FDA has approved a new higher-dose version of injectable semaglutide (Wegovy HD, Novo Nordisk) for both weight loss and long-term weight-loss maintenance. The higher dose, 7.2 mg, produced an ...

The Food and Drug Administration (FDA) on Thursday approved a higher dose of the Wegovy weight loss drug. The manufacturer, Novo Nordisk, increased the semaglutide injection by 4.8 mg to total 7.2 mg.

Add Yahoo as a preferred source to see more of our stories on Google. The FDA-approved Wegovy pill is now available for those looking to lose weight. The Wegovy pill was FDA-approved just last month ...